Viracta Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Viracta Therapeutics

09/08/2024 17:55

* Viracta Therapeutics Inc  VIRX.OQ   VIRX.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 12 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Viracta Therapeutics Inc
is
for a loss of 37 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $5.00​, above​ its last closing price
of $0.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.35       -0.35      -0.23     Beat    34.8
 Dec. 31 2024  -0.34       -0.31      -0.35     Missed  -12.9
 Sep. 30 2023  -0.30       -0.30      -0.33     Missed  -8.2​
 Jun. 30 2023  -0.30       -0.29      -0.32     Missed  -10.3
 ​​Jan.        -0.31       -0.31      -0.32     Missed  -2.4
 1 0001                                                 
 Dec. 31 2022  -0.33       -0.38      -0.27     Beat    29.9​
 Sep. 30 2022  -0.30       -0.30      -0.47     Missed  -54.1
 Jun. 30 2022  -0.30       -0.30      -0.28     Beat    5.9
 This summary was machine generated August 9 at 16:55 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)